0001104659-23-071762.txt : 20230615 0001104659-23-071762.hdr.sgml : 20230615 20230615200507 ACCESSION NUMBER: 0001104659-23-071762 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230613 FILED AS OF DATE: 20230615 DATE AS OF CHANGE: 20230615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Potts Jeannette CENTRAL INDEX KEY: 0001814693 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 231019089 MAIL ADDRESS: STREET 1: C/O FORMA THERAPEUTICS HOLDINGS, INC. STREET 2: 500 ARSENAL STREET, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 4 1 tm2318865-1_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-06-13 0 0001590560 uniQure N.V. QURE 0001814693 Potts Jeannette C/O UNIQURE N.V. PAASHEUVELWEG 25A AMSTERDAM P7 1105BP NETHERLANDS 0 1 0 0 See Remarks 0 Ordinary Shares 2023-06-13 4 A 0 47100 0.0 A 47100 D Option (Right to Buy) 20.18 2023-06-13 4 A 0 81300 0 A 2033-06-13 Ordinary Shares 81300 81300 D The Reporting Person was granted 47,100 restricted share units in connection with the Reporting Person's appointment as Chief Legal and Compliance Officer of the Issuer. The restricted share units were granted as an inducement grant pursuant to Nasdaq listing rule 5635(c)(4). Each restricted share unit represents the contingent right to receive one ordinary share of the Issuer. The restricted share units vest in three approximately equal annual installments, with the first vesting date to occur on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. The option vests over four years, with 25% of the shares underlying such option vesting on the first anniversary of the date of grant and 6.25% of the shares underlying such option vesting quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Chief Legal and Compliance Officer /s/ Christian Klemt, Attorney-in-Fact 2023-06-15